<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00921167</url>
  </required_header>
  <id_info>
    <org_study_id>CRCST-L-0006</org_study_id>
    <nct_id>NCT00921167</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Center for Solid Tumor, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Center for Solid Tumor, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with
      recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months, 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>6 months, 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-control rate</measure>
    <time_frame>6 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>3 weeks, 6 weeks, 9 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Astrocytoma</condition>
  <arm_group>
    <arm_group_label>Bevacizumab/Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab/Irinotecan</intervention_name>
    <description>Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks</description>
    <arm_group_label>Bevacizumab/Irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically diagnosed recurrent anaplastic astrocytoma or recurrent glioblastoma
             multiforme

          -  At least 18 years of age

          -  Performance status of 0 and 1 on the Eastern Cooperative Oncology Group (ECOG)
             criteria

          -  One or more measurable disease

          -  Adequate hematologic (neutrophil count &gt;= 1500/uL, platelets &gt;= 100,000/uL), hepatic
             (transaminase =&lt; upper normal limit (UNL)x2.5, bilirubin level =&lt; UNLx1.5, alkaline
             phosphatase =&lt; UNLx2.5), and renal (creatinine clearance &gt;= 30mL/min)

          -  Expected life time more than at least 2 months

          -  A patients who signed the informed consent prior to the participation in the study

        Exclusion Criteria:

          -  A pregnant or lactating patient

          -  A patient of childbearing potential without being tested for pregnancy at baseline or
             with a positive test. (A premenopausal woman with the amenorrhea period of at least 12
             months or longer is considered to have non-childbearing potential.)

          -  A man or woman of childbearing potential without the willingness to use a
             contraceptive measures during the study

          -  A patient with history of another malignant disease within past 3 years, except
             curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and
             early gastric cancer

          -  Medically uncontrolled serious heart, lung, neurological, psychological, or metabolic
             disease

          -  Uncontrolled serious infection

          -  Enrollment in other study within 30 days

          -  Hemorrhage on baseline radiologic examination

          -  A patient who refused to sign the informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2009</study_first_submitted>
  <study_first_submitted_qc>June 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2009</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Astrocytoma</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

